12 Best High Short Interest Stocks With Highest Upside Potential
BNN Bloomberg (May 29) quoted Investment Decision Research’s Melissa Brown saying inflation above the Fed’s 2% target is pressuring bond yields and could weigh on stocks and bonds. She cited strong Q1 earnings partly from a “stock market wealth effect” amid low consumer sentiment (44.8). The article lists 12 high short-interest stocks; examples include Bentley Systems (Q1 2026 revenue $424.2M, FCF $187.9M) and Spyre Therapeutics (pro forma cash $1.2B).
How this was made
The 30-second read
Why it matters
For BSY and SYRE, the article provides company-specific catalysts (earnings/financing/AI initiatives; clinical data and offering-funded runway) that can drive idiosyncratic trading even if macro remains a headwind.
Market read
Despite being a “best high short interest” roundup, the article includes concrete, catalyst-like updates for BSY and SYRE that can influence near-term positioning.
What to watch
For BSY, execution on AI-driven workflows and ARR durability matters more than the headline AI commitment; for SYRE, Phase 2 induction positivity still leaves later endpoints and safety/efficacy confirmation as key overhangs.
Background
The piece is primarily a high-short-interest stock screener framed around inflation pressuring yields and weakening consumer sentiment, with a stated preference for non-US markets.
Ticker impact
Bentley Systems reported Q1 2026 results, highlighted AI initiatives, and added a $550M term loan to expand flexibility.
Moderate upside bias; likely volatility around any follow-on AI/ARR commentary.
The article provides concrete Q1 datapoints (revenue/ARR/free cash flow) and a specific capital-structure action, both typically supportive for sentiment.
Spyre Therapeutics disclosed positive Phase 2 induction data for SPY001 in ulcerative colitis and an offering funding runway into 2029.
Higher probability of near-term upside as traders price incremental trial readouts and funding durability.
The article cites specific clinical readout positivity and a quantified cash runway from the offering, which are actionable catalyst inputs.
Market effects
AI workflow messaging supports software/engineering-tech sentiment; biotech readouts and funding runway reinforce risk-on appetite for clinical-stage names.
Article emphasizes non-US outperformance, but the included tickers are US-listed; limited direct regional spillover.
Macro inflation/yield pressure is framed as a cross-asset headwind, potentially affecting discount rates for growth/biotech.
Counterpoint
High short-interest “upside” lists can be crowded; macro-driven yield spikes can overwhelm company-specific positives.
Key entities
- companyBentley Systems Inc.
Q1 2026 results, AI initiative emphasis, and new $550M term loan to expand borrowing capacity.
- companySpyre Therapeutics Inc.
Positive Phase 2 induction data for SPY001 in ulcerative colitis and an offering generating $1.2B pro forma cash.
